For the Inventor, By the Inventor

Enter assignee name

Malvern, PA, United States of America

Centocor, Inc.

USPTO Granted Patents = 144

% Expired Patents = 42.4

CIPO Patents = 1

EPO Patents = 2

Trademarks = 5

Forward Citations = 4,139

Loading Chart...

Loading Chart...

166 inventors (with patents filed for the assignee):

David M Knight (55 out of 101 patents)

John Ghrayeb (38 out of 45 patents)

Junming Le (34 out of 37 patents)

4. Jan T Vilcek (34 out of 46 patents)

5. Peter E Daddona (33 out of 57 patents)

6. Scott A Siegel (32 out of 38 patents)

7. Jill M Giles-Komar (20 out of 56 patents)

8. George A Heavner (20 out of 37 patents)

9. Bernard Scallon (19 out of 49 patents)

10. David J Shealy (12 out of 41 patents)

11. Linda Snyder (9 out of 34 patents)

12. Mohit Trikha (9 out of 11 patents)

13. Richard T Dean (8 out of 20 patents)

14. David Peritt (7 out of 30 patents)

15. Marian Kruszynski (6 out of 7 patents)

Core Competencies:

Anti-TNF Antibodies

Monoclonal Antibodies

Anti-IL-6

Anti-Integrin

Anti-IL-12

Inflammatory Diseases

Biopharmaceuticals

Therapeutics

Antibody Compositions

Human GLP-1

Cynomolgus Antibodies

Peptide Treatments

144 patents: Sort by Forward Citations

1. 8361474 - Anti-IL-12 antibody based vectors, host cells, and methods of production and uses (2013-01-29),

2. 8293882 - Anti-tissue factor antibodies and compositions (2012-10-23),

3. 8278415 - Dimeric high affinity EGFR constructs and uses thereof (2012-10-02),

4. 8277809 - CXCL13 antagonists and their use for the treatment of inflammatory diseases (2012-10-02),

5. 8241899 - Anti-TNF antibodies, compositions, methods and uses (2012-08-14),

6. 8114964 - Anti-MCP-1 antibodies, compositions, methods and uses (2012-02-14),

7. 8093068 - Methods for use in human-adapting monoclonal antibodies (2012-01-10),

8. 8071729 - Anti-integrin antibodies, compositions, methods and uses (2011-12-06),

9. 8071333 - Anti-integrin antibodies, compositions, methods and uses (2011-12-06),

10. 8071103 - Pharmaceutical composition comprising a human GLP-1 mimetibody (2011-12-06),

11. 8067191 - Method for detecting IL-16 activity and modulation of IL-16 activity based on rantes proxy protein levels (2011-11-29),

12. 8067003 - Methods of treating conditions using anti-IL-6 antibodies (2011-11-29),

13. 8043616 - sRAGE mimetibody, compositions, methods and uses (2011-10-25),

14. 7982007 - Cynomolgus toll-like receptor 3 (2011-07-19),

15. 7955597 - Anti-IL-6 antibodies, compositions, methods and uses (2011-06-07),

Company Overview

Centocor, Inc., based in Malvern, PA, specializes in the development and manufacturing of biopharmaceuticals, particularly monoclonal antibodies. The company focuses on innovative therapeutics targeting inflammatory diseases through advanced technologies such as anti-TNF antibodies, anti-IL-6, anti-integrin, and anti-IL-12. With a commitment to addressing unmet medical needs, Centocor plays a significant role in the biopharmaceutical landscape, contributing to the advancement of treatment options for various inflammatory conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

144 Patents

#3 in Malvern, PA

#114 in Pennsylvania

#2,722 in US

#5,663 in the World

Malvern, PA, United States of America

Centocor, Inc.

Forward Citations = 4,139

166 inventors:

David M Knight (55 out of 101 patents)

John Ghrayeb (38 out of 45 patents)

Junming Le (34 out of 37 patents)

4. Jan T Vilcek (34 out of 46 patents)

5. Peter E Daddona (33 out of 57 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Centocor, Inc.. Retrieved from https://idiyas.com/company/centocor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…